echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > Competition heats up! Fuhong Hanxuan Beval beads single anti-bio-similar drugs reported on the market.

    Competition heats up! Fuhong Hanxuan Beval beads single anti-bio-similar drugs reported on the market.

    • Last Update: 2020-10-14
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    The listing of the single anti-biosynthetic drug is based on a randomized, double-blind, parallel control, multi-center Phase 3 clinical trial (registration number: CTR20191263) of the first-line treatment of metastatic colorectal cancer in the first-line treatment of HLX04 or the original beva bead monoantigen chemotherapy program (XELOX or mFOLFOX6 program).
    On August 12, Fu Hong Hanxuan announced that the main and secondary purposes of the study had been achieved, and the results showed that the efficacy of the drug for the first-line treatment of metastatic colorectal cancer was equivalent to that of the original drug, and that its safety, tolerance and immunogenicity were similar to those of the original drug, and would be based on the HLX04 treatment of metastatic colorectal cancer, non-squamous non-small cell lung cancer adaptation report.
    beaver bead monoantigen is a recombinant humanized anti-vascular endital growth factor (VEGF) monoantigen.
    VEGF is an important signaling molecule in angiogenesic process, overexeracted in a variety of tumor endoblast cells.
    Beva bead monoantitor inhibits the transmission of PI3K-Akt/PKB and Ras-Raf-MEK-ERK signaling paths by blocking veGF from binding to VEGF receptors on the surface of endoblast cells, blocking the production and blood supply of the tumor's new blood vessels, thereby "starving" the tumor.
    Because of its wide range of mechanism-adaptive mechanisms and its use as a base drug for a variety of treatments, Beval pearl monoantigen (commodity name: Aviva) has been Roche's core heavyweight variety, with global sales reaching CHF 6.85 billion and CHF 7.07 billion in 2018 and 2019, respectively.
    Europe and the United States remain the core areas of ® sales: sales in the United States and the European Union in 2019 will be 3,019,19 million Swiss francs and 1,794 million Swiss francs, respectively.
    At present, in addition to Qilu, Xinda's Beva Pearl single anti-injection has been approved for the market, Hengrui Pharmaceuticals, Green Leaf Pharmaceuticals, Baiotai, Beda Pharmaceuticals, Dongyu Pharmaceuticals Beval pearl single anti-injections have been reported, if according to the reported production time, Fuhong Hanzhu's Beval Pearl single anti-injection is expected to become the 8th Beval pearl single anti-biological similar drugs.
    addition, Jia and Bio, Zhengda Tianqing, Hualan Gene, Shenzhou Cells and Anke Bio are in Phase 3 clinical trials.
    in the international market, Avitin's main patents expire in the United States and the European Union in 2019 and 2020, respectively, and many pharmaceutical companies have started development projects for beva beads.
    by the end of 2019, Ajin/Aer Ling's Mvasi and Pfizer's Zirabev have been approved for listing in the U.S. and Europe, while some varieties are at different stages of listing applications and clinical studies.
    Has long been one of Roche's best-selling oncology drugs in the world, and sales of Hercetin and Meromyl are still growing among Roche's top three oncology drugs in 2019.
    , but affected by generic drugs, outbreaks and so on, Roche's first-half 2020 results showed that Avetin fell 18% year-on-year.
    2017, Beval pearl single resistance was included in the National Health Insurance Directory Category B, the standard of payment for health insurance is 1998 yuan (100 mg / bottle), in 2018 further reduced to 1934 yuan (10 0mg/bottle), and successfully renewed into the 2019 edition of the health insurance catalog, the sharp decline in payment prices makes the market access to products greatly improved, in recent years, the sales of original varieties in the domestic market has maintained an average annual growth rate of more than 40%, 2019 sales are expected to exceed 3.2 billion yuan.
    Wanlian Securities pointed out that the follow-up with better cost-effective domestic similar items listed one after another, the overall market space of the domestic beval beads single resistance will be further opened, it is expected that by 2023, the domestic beval beads single anti-similars market size will reach 6.4 billion yuan.
    addition, according to the National Health Insurance Administration to include biological drugs in the collection, the future price of the drug market will be further reduced, competition between enterprises will become more and more intense.
    .
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.